Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ME3 | Q16798 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34468338 | 0.90 | EPHX2 (0.62) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL30718482 | 0.90 | EPHX2 (0.62) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL15055182 | 0.90 | EPHX2 (0.62) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2469256 | 0.88 | EPHX2 (0.83) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL6009189 | 0.86 | EPHX2 (0.61) | EPHX2SIGMAR1 | |
| SCHEMBL2753089 | 0.84 | EPHX2 (0.96) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL5049597 | 0.84 | EPHX2 (0.90) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL652791 | 0.84 | LMNA (0.79) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL16825757 | 0.84 | SIGMAR1 (0.58) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL3638096 | 0.84 | SIGMAR1 (0.58) | EPHX2SIGMAR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| US-8772319-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120208847-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8114379-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| CN-100591679-C | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators | JANSSEN PHARMACEUTICA NV | 2010-02-24 | — | — | CN | disclosed |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2008100564-A1 | LTA4H MODULATORS AND USES THEROF | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1140837-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| CN-1330637-A | Compounds useful in treatment of infammatory diseases | GLAXO GROUP LTD (GB) | 2002-01-09 | — | — | CN | disclosed |
| EP-1140837-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000071171-A2 | SIGMA-1 LIGANDS FOR DETERMINING CARCINOMA PROLIFERATIVE STATUS | WAKE FOREST UNIVERSITY (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000037444-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2000-06-29 | — | — | WO | disclosed |
| EP-0064255-B1 | BENZOPYRANYL ETHERS, PROCESS FOR THEIR PREPARATION AND MEDICINE CONTAINING THOSE COMPOUNDS AND INTERMEDIATES | Roche Diagnostics GmbH (DE) | 1984-12-12 | — | — | EP | disclosed |
| US-4428955-A | ALLERGIC DISEASES | BOEHRINGER MANNHEIM GMBH (DE) | 1984-01-31 | — | — | US | disclosed |
| EP-0064255-A1 | Benzopyranyl ethers, process for their preparation and medicine containing those compounds and intermediates | Roche Diagnostics GmbH (DE) | 1982-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10207993-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | EPHX2 2847/4885SIGMAR1 2089/4885MEN1 2815/4885 |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | NR2E3, DRD2, HCRTR1 | EPHX2 2419/4885SIGMAR1 16/4885MEN1 4462/4885 |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | EPHX2 2995/4885SIGMAR1 1761/4885MEN1 3373/4885 |
| US-20120208847-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | SNCA, NLN, DRD2 | EPHX2 4319/4885SIGMAR1 521/4885MEN1 4030/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | EPHX2 2995/4885SIGMAR1 1761/4885MEN1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.